Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3[1].
in vivo
Zenocutuzumab (2.5-25 mg/kg; i.p.; once weekly; for 28 days) causes a statistically significant reduction of growth, including tumor regression[1].
Animal Model:
6 to 12-week-old female NSG (LUAD-0061AS3), BALB/c nude (OV-10–0050) or athymic nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors[1].
Dosage:
2.5 mg/kg, 8 mg/kg, or 25 mg/kg
Administration:
i.p.; once weekly; for 28 days
Result:
Blocked growth of lung and ovarian cancer PDX models.
References
[1] Alison M Schram, et al. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247. DOI:10.1158/2159-8290.CD-21-1119
